Developer docs
API playgroundTry for free, no card

Search company profiles

George Medicines

Full company profile

uuid0000jbq

Namestring
George Medicines
Legal namestring
George Medicines Pty Limited
Company typeenum
Private
Founded yearint
2021
Descriptiontext

George Medicines is a late-stage biopharmaceutical company that develops single-pill, multi-mechanism combination therapies for cardiometabolic diseases, primarily hypertension and type 2 diabetes. The company's core technology reformulates established, off-patent drugs at novel ultra-low doses into proprietary fixed-dose combinations; its lead product GMRx2/WIDAPLIK combines telmisartan (angiotensin II receptor blocker), amlodipine (calcium channel blocker), and indapamide (thiazide-like diuretic) in three dose strengths, including two lower than any previously available single-pill combination. WIDAPLIK received FDA approval in June 2025 as the first and only triple-combination therapy approved for initial treatment of hypertension, supported by two pivotal Phase III trials published in The Lancet, JACC, and the NEJM, with additional evidence from the TRIDENT stroke outcomes trial showing a 39% relative risk reduction in recurrent intracerebral hemorrhage stroke. GMRx4, a triple-combination candidate for type 2 diabetes, is in Phase II development.

The company operates an asset-light, partner-led commercialization model under which it retains ownership of its formulations and grants exclusive regional licensing and supply agreements to established pharmaceutical companies responsible for regulatory submissions, marketing, sales, and distribution in their territories. As of mid-2026, six regional agreements are in place covering the US (Azurity Pharmaceuticals), Australia/New Zealand (Arrotex), Korea (Ahngook Pharmaceutical), Brazil (Biolab Farmacêutica), Canada/Mexico/Colombia/Central America (Bausch Health), and Southeast Asia (Orient EuroPharma). Revenue is generated through upfront licensing fees, regulatory and commercial milestone payments, and tiered royalties on sales. The company is a venture-backed spin-out from George Health, the commercial arm of The George Institute for Global Health, with Brandon Capital as a key institutional backer. Headcount is reported at 1-10 employees, with clinical, regulatory, and formulation operations outsourced to specialized partners including George Clinical, Imperial College London's ICTU, Piramal Pharma Solutions, and Pharmalex (Cencora).

Short descriptiontext

George Medicines is a London-based biopharmaceutical company developing proprietary single-pill, multi-mechanism combination therapies for cardiometabolic diseases, with FDA-approved WIDAPLIK for hypertension and GMRx4 in Phase II for type 2 diabetes, commercialized globally via regional licensing partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hypertension therapeutics, fixed-dose combinations, cardiometabolic pharmaceuticals, single-pill combinations, combination drug therapies
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiometabolic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Fees and Upfront Payments
TypeLicensing Royalties
Description

George Medicines receives upfront licensing fees from regional partners upon execution of licensing and supply agreements for GMRx2 commercialization rights.

george-medicines.com
2Regulatory and Commercial Milestone Payments
TypeLicensing Royalties
Description

Company is eligible for regulatory milestone payments upon approval and commercial milestone payments based on sales performance as specified in licensing agreements with regional partners.

george-medicines.com
3Tiered Royalties on Sales
TypeLicensing Royalties
Description

Future recurring revenue stream through stepped/tiered royalty rates on sales of GMRx2 in licensed territories, providing ongoing revenue as product adoption grows.

george-medicines.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1WIDAPLIK
Description

FDA-approved single pill combination treatment for hypertension containing telmisartan, amlodipine and indapamide

george-medicines.com
Core offering1 text field

George Medicines develops and commercializes innovative single-pill, multi-mechanism combination therapies that combine established medicines at novel low-dose strengths to treat cardiometabolic diseases. Its lead product WIDAPLIK (GMRx2) is an FDA-approved triple combination of telmisartan, amlodipine and indapamide for the treatment of hypertension, including as initial therapy. The company also has GMRx4 in Phase II development for type 2 diabetes. It commercializes via exclusive regional licensing and supply partnerships rather than direct sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 39% relative risk reduction for recurrent stroke in patients with prior intracerebral hemorrhage
+4 more records
Product overview1 text field

George Medicines develops innovative single-pill, multi-mechanism combinations of existing treatments for cardiometabolic diseases. The core product portfolio includes GMRx2/WIDAPLIK (a triple combination of telmisartan, amlodipine, and indapamide for hypertension, FDA-approved in 2025) and GMRx4 (a triple combination for type 2 diabetes in Phase II development). These fixed-dose combinations use lower doses of established medicines combined in single pills to improve efficacy, safety, and patient adherence compared to traditional multi-pill regimens.

Product and service2 records
1WIDAPLIK (GMRx2)
CategoryHypertension therapeutics — fixed-dose triple combination
Description

FDA-approved single-pill triple combination therapy containing telmisartan (angiotensin II receptor blocker), amlodipine (calcium channel blocker) and indapamide (thiazide-like diuretic), available in three dose strengths: 10/1.25/0.625 mg; 20/2.5/1.25 mg; and 40/5/2.5 mg. Approved as initial therapy for hypertension in adults, and the first and only FDA-approved triple combination for initial hypertension treatment. Commercialized via regional licensing partners (Azurity Pharmaceuticals in the US).

2GMRx4
CategoryType 2 diabetes therapeutics — fixed-dose triple combination
Description

Single-pill triple combination candidate in Phase II development for first-line treatment of type 2 diabetes, combining three best-in-class type 2 diabetes treatments in an ultra-low-dose, single-pill formulation to deliver synergistic efficacy with improved tolerability and adherence.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-16
Description

Exclusive licensing and supply agreement granting Arrotex exclusive rights to commercialize GMRx2 in Australia and New Zealand. Arrotex is Australia's largest pharmaceutical supplier by prescription volume. George Medicines receives upfront licensing fee, commercial milestones, and tiered royalties. Arrotex to seek TGA (Australia) and Medsafe (NZ) regulatory approvals.

2Ahngook Pharmaceutical Co. Ltd
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-11
Description

Exclusive licensing and supply agreement granting Ahngook Pharm exclusive rights to seek regulatory approval and commercialize GMRx2 in Korea. George Medicines receives upfront licensing fee plus regulatory and commercial milestone payments, and stepped royalties on sales. Ahngook Pharm is responsible for seeking regulatory approval with support from George Medicines.

george-medicines.com
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive licensing agreement for US commercialization of WIDAPLIK (GMRx2). Azurity holds rights to commercialize the FDA-approved triple combination hypertension treatment in the United States.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive licensing agreement for commercialization of GMRx2 in Canada, Mexico, Colombia, and Central America.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive licensing agreement for commercialization of GMRx2 in Brazil.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive licensing agreement for commercialization of GMRx2 in Southeast Asia.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

George Medicines is a spin-out company from The George Institute for Global Health, one of the world's leading medical research institutes. The company uses the Institute's research base and scientific expertise for late-stage development of single-pill combination therapies. The George Institute conducts investigator-initiated trials including the TRIDENT stroke outcomes trial.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Contract pharmaceutical partner providing formulation development services for George Medicines' pipeline candidates.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical development partner providing clinical trial management services, particularly for the Phase III program across multiple countries.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic partner collaborating on Phase III clinical trials, particularly the placebo-controlled trial expanded into the UK, and investigator-initiated studies.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical research organization partner supporting trial operations in Sri Lanka and other South Asian regions.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical development partner providing regulatory and clinical development support services.

13Medisanté
Strategic tierSupportingTypeTechnology or Integration
Description

Global innovator in medical IoT collaborating with George Medicines to enable seamless decentralized data collection in Phase III clinical trials through remote monitoring technology.

george-medicines.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cipla is a leading Indian generics manufacturer with a large portfolio of cardiovascular fixed-dose combinations, including its own polypill program for cardiovascular prevention. Highly comparable to George Medicines because it sells multi-drug FDCs targeting hypertension and cardiovascular disease, often at scale across emerging markets through licensing and partnerships.

2Ferrer Internacional
TypeDirect peer
Description

Ferrer commercializes Trinomia, a single-pill triple combination of aspirin, atorvastatin, and ramipril for secondary cardiovascular prevention. Closest direct comparable to George Medicines' WIDAPLIK given the explicit polypill/FDC architecture, cardiovascular indication, and partner-led commercialization model.

TypeDirect peer
Description

Zydus is an Indian pharma group with a deep cardiovascular generics and FDC franchise and a history of polypill development. Comparable because it competes in the same cardiometabolic FDC category and pursues similar single-pill combination strategies across global markets.

TypeDirect peer
Description

Glenmark has a substantial branded-generic cardiometabolic portfolio, including several fixed-dose combinations for hypertension and diabetes. Relevant direct peer as it competes with novel FDCs in similar patient segments and markets.

TypeDirect peer
Description

Dr. Reddy's combines generics with a branded cardiometabolic franchise across India, emerging markets and the US. Comparable to George Medicines in its emphasis on combination products and out-licensing for territory-specific commercialization.

6Sun Pharmaceutical Industries
TypeDirect peer
Description

Sun Pharma operates one of India's largest cardiology FDC portfolios alongside specialty and generics businesses. Direct peer because it sells competing single-pill combinations for hypertension and cardiovascular disease globally, including through regional licensing arrangements.

TypeBroad incumbent
Description

AstraZeneca is a major incumbent in cardiovascular and cardiometabolic medicine with products like Brilinta, Crestor and a large hypertension and diabetes portfolio. Broadly comparable as a global cardiometabolic incumbent, and notable because George Medicines' current CEO Mark Mallon previously led AstraZeneca's international operations.

TypeBroad incumbent
Description

Bayer is a global incumbent in cardiovascular medicine with products such as Xarelto, Adempas, and Eylea. Comparable at the category level because it serves the same physician prescribers and hypertension/cardiovascular patients, though Bayer's portfolio is broader and not focused on FDCs.

TypeBroad incumbent
Description

Novartis is a major incumbent in cardiometabolic disease via Entresto, Leqvio, and a hypertension and diabetes portfolio. Comparable as a global cardiovascular player whose physician-facing commercial model and clinical evidence base set the benchmark George Medicines' partners must compete against.

TypeBroad incumbent
Description

Viatris is a large generics and branded pharma company with a deep cardiovascular franchise, including combinations targeting hypertension and lipid management. Comparable as a broad incumbent that George Medicines' licensing partners (e.g. Bausch Health) compete with in the cardiovascular generics and FDC space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

George Medicines

Cardiometabolic Pharmaceuticalsgeorge-medicines.com

George Medicines is a London-based biopharmaceutical company developing proprietary single-pill, multi-mechanism combination therapies for cardiometabolic diseases, with FDA-approved WIDAPLIK for hypertension and GMRx4 in Phase II for type 2 diabetes, commercialized globally via regional licensing partners.

What George Medicines does

George Medicines is a late-stage biopharmaceutical company that develops single-pill, multi-mechanism combination therapies for cardiometabolic diseases, primarily hypertension and type 2 diabetes. The company's core technology reformulates established, off-patent drugs at novel ultra-low doses into proprietary fixed-dose combinations; its lead product GMRx2/WIDAPLIK combines telmisartan (angiotensin II receptor blocker), amlodipine (calcium channel blocker), and indapamide (thiazide-like diuretic) in three dose strengths, including two lower than any previously available single-pill combination. WIDAPLIK received FDA approval in June 2025 as the first and only triple-combination therapy approved for initial treatment of hypertension, supported by two pivotal Phase III trials published in The Lancet, JACC, and the NEJM, with additional evidence from the TRIDENT stroke outcomes trial showing a 39% relative risk reduction in recurrent intracerebral hemorrhage stroke. GMRx4, a triple-combination candidate for type 2 diabetes, is in Phase II development.

The company operates an asset-light, partner-led commercialization model under which it retains ownership of its formulations and grants exclusive regional licensing and supply agreements to established pharmaceutical companies responsible for regulatory submissions, marketing, sales, and distribution in their territories. As of mid-2026, six regional agreements are in place covering the US (Azurity Pharmaceuticals), Australia/New Zealand (Arrotex), Korea (Ahngook Pharmaceutical), Brazil (Biolab Farmacêutica), Canada/Mexico/Colombia/Central America (Bausch Health), and Southeast Asia (Orient EuroPharma). Revenue is generated through upfront licensing fees, regulatory and commercial milestone payments, and tiered royalties on sales. The company is a venture-backed spin-out from George Health, the commercial arm of The George Institute for Global Health, with Brandon Capital as a key institutional backer. Headcount is reported at 1-10 employees, with clinical, regulatory, and formulation operations outsourced to specialized partners including George Clinical, Imperial College London's ICTU, Piramal Pharma Solutions, and Pharmalex (Cencora).

George Medicines firmographics

Firmographics
Name
George Medicines
Legal name
George Medicines Pty Limited
Website
https://george-medicines.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
George Medicines is a London-based biopharmaceutical company developing proprietary single-pill, multi-mechanism combination therapies for cardiometabolic diseases, with FDA-approved WIDAPLIK for hypertension and GMRx4 in Phase II for type 2 diabetes, commercialized globally via regional licensing partners.
Ownership category
akta.pro rank

George Medicines industry classification

Industry
Product category
Cardiometabolic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Hypertension therapeutics
  • Fixed-dose combinations
  • Cardiometabolic pharmaceuticals
  • Single-pill combinations
  • Combination drug therapies

Where George Medicines is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

George Medicines business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing Fees and Upfront Payments: George Medicines receives upfront licensing fees from regional partners upon execution of licensing and supply agreements for GMRx2 commercialization rights.
  2. Regulatory and Commercial Milestone Payments: Company is eligible for regulatory milestone payments upon approval and commercial milestone payments based on sales performance as specified in licensing agreements with regional partners.
  3. Tiered Royalties on Sales: Future recurring revenue stream through stepped/tiered royalty rates on sales of GMRx2 in licensed territories, providing ongoing revenue as product adoption grows.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

George Medicines product offering

Product offering

Core offering

George Medicines develops and commercializes innovative single-pill, multi-mechanism combination therapies that combine established medicines at novel low-dose strengths to treat cardiometabolic diseases. Its lead product WIDAPLIK (GMRx2) is an FDA-approved triple combination of telmisartan, amlodipine and indapamide for the treatment of hypertension, including as initial therapy. The company also has GMRx4 in Phase II development for type 2 diabetes. It commercializes via exclusive regional licensing and supply partnerships rather than direct sales.

Product overview

George Medicines develops innovative single-pill, multi-mechanism combinations of existing treatments for cardiometabolic diseases. The core product portfolio includes GMRx2/WIDAPLIK (a triple combination of telmisartan, amlodipine, and indapamide for hypertension, FDA-approved in 2025) and GMRx4 (a triple combination for type 2 diabetes in Phase II development). These fixed-dose combinations use lower doses of established medicines combined in single pills to improve efficacy, safety, and patient adherence compared to traditional multi-pill regimens.

Differentiator

Problem solved

Functional benefit

Brands

  • WIDAPLIK: FDA-approved single pill combination treatment for hypertension containing telmisartan, amlodipine and indapamide

Products and services

  • WIDAPLIK (GMRx2) FDA-approved single-pill triple combination therapy containing telmisartan (angiotensin II receptor blocker), amlodipine (calcium channel blocker) and indapamide (thiazide-like diuretic), available in three dose strengths: 10/1.25/0.625 mg; 20/2.5/1.25 mg; and 40/5/2.5 mg. Approved as initial therapy for hypertension in adults, and the first and only FDA-approved triple combination for initial hypertension treatment. Commercialized via regional licensing partners (Azurity Pharmaceuticals in the US).
  • GMRx4 Single-pill triple combination candidate in Phase II development for first-line treatment of type 2 diabetes, combining three best-in-class type 2 diabetes treatments in an ultra-low-dose, single-pill formulation to deliver synergistic efficacy with improved tolerability and adherence.

Quantifiable outcome

  • 39% relative risk reduction for recurrent stroke in patients with prior intracerebral hemorrhage
  • +4 more outcomes

Companies that use George Medicines

Customer profile

Segments3 records

Ideal customer profiles1 record

George Medicines technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

George Medicines partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered major, core and supporting.

  • Arrotex PharmaceuticalsmajorOEM/ Whitelabel/ Licensing Partner · 16 March 2026Exclusive licensing and supply agreement granting Arrotex exclusive rights to commercialize GMRx2 in Australia and New Zealand. Arrotex is Australia's largest pharmaceutical supplier by prescription volume. George Medicines receives upfront licensing fee, commercial milestones, and tiered royalties. Arrotex to seek TGA (Australia) and Medsafe (NZ) regulatory approvals.
  • Ahngook Pharmaceutical Co. LtdmajorOEM/ Whitelabel/ Licensing Partner · 11 March 2026Exclusive licensing and supply agreement granting Ahngook Pharm exclusive rights to seek regulatory approval and commercialize GMRx2 in Korea. George Medicines receives upfront licensing fee plus regulatory and commercial milestone payments, and stepped royalties on sales. Ahngook Pharm is responsible for seeking regulatory approval with support from George Medicines.
  • Azurity PharmaceuticalsmajorOEM/ Whitelabel/ Licensing PartnerExclusive licensing agreement for US commercialization of WIDAPLIK (GMRx2). Azurity holds rights to commercialize the FDA-approved triple combination hypertension treatment in the United States.
  • Bausch HealthmajorOEM/ Whitelabel/ Licensing PartnerExclusive licensing agreement for commercialization of GMRx2 in Canada, Mexico, Colombia, and Central America.
  • Biolab FarmacêuticamajorOEM/ Whitelabel/ Licensing PartnerExclusive licensing agreement for commercialization of GMRx2 in Brazil.
  • Orient EuroPharmamajorOEM/ Whitelabel/ Licensing PartnerExclusive licensing agreement for commercialization of GMRx2 in Southeast Asia.
  • The George Institute for Global HealthcoreStrategic or Co-development PartnerGeorge Medicines is a spin-out company from The George Institute for Global Health, one of the world's leading medical research institutes. The company uses the Institute's research base and scientific expertise for late-stage development of single-pill combination therapies. The George Institute conducts investigator-initiated trials including the TRIDENT stroke outcomes trial.
  • Piramal Pharma SolutionssupportingStrategic or Co-development PartnerContract pharmaceutical partner providing formulation development services for George Medicines' pipeline candidates.
  • George ClinicalsupportingStrategic or Co-development PartnerClinical development partner providing clinical trial management services, particularly for the Phase III program across multiple countries.
  • Imperial Clinical Trials Unit (ICTU) at Imperial College LondonsupportingStrategic or Co-development PartnerAcademic partner collaborating on Phase III clinical trials, particularly the placebo-controlled trial expanded into the UK, and investigator-initiated studies.
  • RemediumOnesupportingStrategic or Co-development PartnerClinical research organization partner supporting trial operations in Sri Lanka and other South Asian regions.
  • Pharmalex (Cencora)supportingStrategic or Co-development PartnerClinical development partner providing regulatory and clinical development support services.
  • MedisantésupportingTechnology or IntegrationGlobal innovator in medical IoT collaborating with George Medicines to enable seamless decentralized data collection in Phase III clinical trials through remote monitoring technology.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

George Medicines competitors and assessment

Company assessment

Direct peers

  • Cipla: Cipla is a leading Indian generics manufacturer with a large portfolio of cardiovascular fixed-dose combinations, including its own polypill program for cardiovascular prevention. Highly comparable to George Medicines because it sells multi-drug FDCs targeting hypertension and cardiovascular disease, often at scale across emerging markets through licensing and partnerships.
  • Ferrer Internacional: Ferrer commercializes Trinomia, a single-pill triple combination of aspirin, atorvastatin, and ramipril for secondary cardiovascular prevention. Closest direct comparable to George Medicines' WIDAPLIK given the explicit polypill/FDC architecture, cardiovascular indication, and partner-led commercialization model.
  • Zydus Lifesciences: Zydus is an Indian pharma group with a deep cardiovascular generics and FDC franchise and a history of polypill development. Comparable because it competes in the same cardiometabolic FDC category and pursues similar single-pill combination strategies across global markets.
  • Glenmark Pharmaceuticals: Glenmark has a substantial branded-generic cardiometabolic portfolio, including several fixed-dose combinations for hypertension and diabetes. Relevant direct peer as it competes with novel FDCs in similar patient segments and markets.
  • Dr. Reddy's Laboratories: Dr. Reddy's combines generics with a branded cardiometabolic franchise across India, emerging markets and the US. Comparable to George Medicines in its emphasis on combination products and out-licensing for territory-specific commercialization.
  • Sun Pharmaceutical Industries: Sun Pharma operates one of India's largest cardiology FDC portfolios alongside specialty and generics businesses. Direct peer because it sells competing single-pill combinations for hypertension and cardiovascular disease globally, including through regional licensing arrangements.

Broad incumbents

  • AstraZeneca: AstraZeneca is a major incumbent in cardiovascular and cardiometabolic medicine with products like Brilinta, Crestor and a large hypertension and diabetes portfolio. Broadly comparable as a global cardiometabolic incumbent, and notable because George Medicines' current CEO Mark Mallon previously led AstraZeneca's international operations.
  • Bayer: Bayer is a global incumbent in cardiovascular medicine with products such as Xarelto, Adempas, and Eylea. Comparable at the category level because it serves the same physician prescribers and hypertension/cardiovascular patients, though Bayer's portfolio is broader and not focused on FDCs.
  • Novartis: Novartis is a major incumbent in cardiometabolic disease via Entresto, Leqvio, and a hypertension and diabetes portfolio. Comparable as a global cardiovascular player whose physician-facing commercial model and clinical evidence base set the benchmark George Medicines' partners must compete against.
  • Viatris: Viatris is a large generics and branded pharma company with a deep cardiovascular franchise, including combinations targeting hypertension and lipid management. Comparable as a broad incumbent that George Medicines' licensing partners (e.g. Bausch Health) compete with in the cardiovascular generics and FDC space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

George Medicines social profiles

Digital presence

George Medicines compliance and trust

Trust signal

Compliance3 records

George Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

George Medicines leadership team

Management profile

Number of profiles

Profiles10 records

George Medicines subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

George Medicines funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

George Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about George Medicines

What does George Medicines do?

George Medicines develops and commercializes innovative single-pill, multi-mechanism combination therapies that combine established medicines at novel low-dose strengths to treat cardiometabolic diseases. Its lead product WIDAPLIK (GMRx2) is an FDA-approved triple combination of telmisartan, amlodipine and indapamide for the treatment of hypertension, including as initial therapy. The company also has GMRx4 in Phase II development for type 2 diabetes. It commercializes via exclusive regional licensing and supply partnerships rather than direct sales.

Is George Medicines a public or private company?

George Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was George Medicines founded?

George Medicines was founded in 2021. It employs 11 to 50 people.

Where is George Medicines based?

George Medicines is headquartered in London, United Kingdom, in the Europe region.

How does George Medicines make money?

Three revenue lines are on record. Licensing Fees and Upfront Payments are the primary driver. The others are regulatory and Commercial Milestone Payments and tiered Royalties on Sales.

Who are George Medicines's main competitors?

Direct peers on record are Cipla, Ferrer Internacional, Zydus Lifesciences, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories and Sun Pharmaceutical Industries. Broad incumbents are AstraZeneca, Bayer, Novartis and Viatris.

Does George Medicines have an API?

No public API is recorded for George Medicines.

What industry is George Medicines in?

George Medicines's product category is Cardiometabolic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialTRIDENT Post-Hoc Analysis Of Low-Dose Triple Combination Therapy By Kidney Function In People With Prior Intracerebral Hemorrhage Presented At American Heart Association's Scientific Sessions 2026George Medicines presented a post-hoc analysis of the TRIDENT trial at AHA Scientific Sessions 2026, showing GMRx2 reduced recurrent stroke risk by 39% (HR 0.61) across kidney function groups. Serious adverse events were balanced overall, with numerically lower rates in the GMRx2 group. The effect was consistent regardless of eGFR.GlobeNewswireTRIDENT post-hoc analysis of low-dose triple combination therapy by kidney function in people with prior intracerebral hemorrhage presented at American Heart Association’s Scientific Sessions 2026George Medicines presented post-hoc analysis of the TRIDENT trial at AHA Scientific Sessions 2026, showing GMRx2 reduced recurrent stroke risk by 39% (HR 0.61) across kidney function groups. Serious adverse events were balanced overall, with numerically lower rates in the GMRx2 group. The effect was consistent regardless of eGFR.GlobeNewswireGeorge Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical OperationsGeorge Medicines, a late-stage biopharmaceutical company focused on cardiometabolic disease, has appointed Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations, effective immediately. Walsh brings over 20 years of pharmaceutical supply chain leadership experience, most recently serving as European Supply Chain & Technical Director at Otsuka Pharmaceutical Europe Ltd. The appointment is intended to support the company's global commercial expansion of GMRx2, its flagship triple-combination hypertension therapy, which has licensing agreements with pharmaceutical partners across multiple regions including Australia, Brazil, Canada, the United States, Mexico, Colombia, Central America, Korea, and Southeast Asia.GlobeNewswireGeorge Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intGeorge Medicines announced that its GMRx2 triple-therapy reduced recurrent stroke risk by 39% in patients with prior intracerebral hemorrhage, per the TRIDENT trial published in the New England Journal of Medicine. The study of 1,670 patients also lowered mean systolic blood pressure by 9mmHg over three years, with safety consistent to prior studies.GlobeNewswireGeorge Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreementGeorge Medicines granted Arrotex exclusive rights to commercialize GMRx2, a triple-antihypertensive single-pill combination, in Australia and New Zealand. The deal includes an upfront licensing fee, commercial milestones, and a tiered royalty. Arrotex will seek regulatory approval from Australia's TGA and New Zealand's MMDSA.BioSpaceGeorge Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreementGeorge Medicines has entered into an exclusive licensing and supply agreement granting Arrotex Pharmaceuticals exclusive rights to commercialize GMRx2, its single-pill triple-combination hypertension treatment, in Australia and New Zealand. Under the terms, George Medicines will receive an upfront licensing fee, commercial milestone payments, and tiered royalties on future sales, while Arrotex will seek regulatory approval from Australia's Therapeutic Goods Administration and New Zealand's Medicines and Medical Devices Safety Authority. The agreement advances George Medicines' global commercialization strategy for a product targeting a significant unmet need, with approximately one in three adults in both countries affected by hypertension.GlobeNewswireGeorge Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in KoreaGeorge Medicines signed an exclusive licensing and supply agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea. The company will receive an upfront licensing fee and is eligible for regulatory and commercial milestone payments, plus a stepped royalty on sales. This is the fifth major licensing deal for GMRx2, expanding its global commercialization strategy.The Pharma LetterAhngook to market George Medicines’ hypertension drug in KoreaGeorge Medicines entered an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical. The deal grants Ahngook exclusive rights to seek regulatory approval of and commercialize GMRx2 in Korea.GlobeNewswireGeorge Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast AsiaGeorge Medicines signed an exclusive licensing and supply agreement with Orient EuroPharma to commercialize GMRx2 in Southeast Asia. The company receives an upfront fee and is eligible for regulatory and commercial milestones, plus stepped royalties. Further partnerships are anticipated as George Medicines expands global access.GlobeNewswireGeorge Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025George Medicines presented long-term data from a 52-week open-label extension of its Phase 3 study on GMRx2 (WIDAPLIK), a single-pill triple combination for hypertension. In 50 participants, mean home BP was maintained at 120/78 mmHg, with 56% home and 88% clinic BP control, and no discontinuations due to adverse events.